Novartis treatment for vision loss meets goals in study

February 27, 2015 4:31 PM

2 0

ZURICH (Reuters) - Swiss drugmaker Novartis said on Friday its treatment for a leading cause of age-related blindness had met its primary goals in a study and could potentially pave the way for less frequent dosing compared to a drug already on the market.

Developed by Novartis's eyecare unit Alcon, the RTH258 drug is intended to treat wet age-related macular degeneration (AMD), which causes severe loss of vision in the over 50s and occurs when the center of the retina, or macula, deteriorates.

Read more

To category page